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Abstract.  
Mutations in the LGI1/Epitempin gene cause autosomal dominant lateral 
temporal lobe epilepsy (ADLTE), a partial epilepsy characterized by the 
presence of auditory seizures. However, not all the pedigrees with a 
phenotype consistent with ADLTE show mutations in LGI1/Epitempin, or 
evidence for linkage to the 10q24 locus. Other authors as well as ourselves 
have found an internal repeat (EPTP, pfam# PF03736) that allowed the 
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identification of three other genes sharing a sequence and structural 
similarity with LGI1/Epitempin. In this work, we present the sequencing of 
these genes in a set of ADLTE families without mutations in both 
LGI1/Epitempin and sporadic cases. No analyzed polymorphisms modified 
susceptibility in either the familial or sporadic forms of this partial epilepsy. 
1. Introduction 
Autosomal dominant lateral temporal epilepsy (ADLTE, OMIM#600512) 
is a partial epilepsy characterized by a juvenile-adult onset, rare seizures 
and with good response to anti-epileptic treatments, although recurrence 
after drug withdrawal is frequently observed. Electroencephalographic 
recordings of patients usually show unilateral or bilateral epileptiform 
activity over the temporal-occipital regions. Ottman and colleagues first 
described this disorder on a large pedigree that they mapped to 10q24 
(Ottman et al., 1995), and this linkage was later confirmed by us (Poza et 
al., 1999). Since then, other pedigrees have been described with a clinical 
syndrome consistent with ADLTE, but without definite evidence of linkage to 
10q24 (Mautner et al., 2000; Michelucci et al., 2000; Brodtkorb et al., 
2002). In 2002, three different groups reported mutations in LGI1/Epitempin 
among those families previously linked to 10q24 (Gu et al., 2002; 
Kalachikov et al., 2002; Morante-Redolat et al., 2002). These were the first 
mutations in epilepsy to affect a non-coding gene for either an ion channel 
or a neurotransmitter receptor. LGI1/Epitempin is a gene with an unclear 
function. It was originally isolated as a tumor suppressor gene since its 
expression was reduced or missing in the T98G glioblastoma cell line, in 
which it is rearranged as a result of a t(10;19)(q24;q13) balanced 
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translocation (Chernova et al., 1998). Krex and coworkers suggested that 
the functional relationship between LGI1/Epitempin and glioblastoma 
formation could be mediated through a different molecule that regulates its 
expression (Krex et al., 2002). Nevertheless, Kunapuli and colleagues were 
unable to replicate their results, and they went further by proposing that 
LGI1/Epitempin not only regulates cell proliferation in T98G cells, but also 
invasiveness (Kunapuli et al., 2003). Finally, this same group proposed that 
the latter action of LGI1/Epitempin was mediated by driving the expression 
of metalloproteinases through the ERK 1/2 pathway (Kunapuli et al., 2004). 
Recently, Senechal et al. found that LGI1/Epitempin is a secreted protein, 
and that mutations in this gene inhibited the secretion of the protein without 
apparently affecting its synthesis (Senechal et al., 2005). 
The LGI1/Epitempin protein is characterized by the existence of two 
separate domains. The N-terminal region contains a putative signal peptide 
followed by 3 leucine-rich repeats (LRRs), which are flanked by cysteine-rich 
domains. On the C-terminal part of the protein, there are 7 copies of an 
internal repeat of 40-43 residues known as EPTP repeat (Pfam 7.2 
#PF03736)(Staub et al., 2002). This structural disposition defined a new 
gene family that includes three other members (LGI2, LGI3 and LGI4), 
which are mapped to 4p15.2, 8p21.3 and 19q13.12, respectively. In addition 
to these three genes which have a structure similar to LGI1, a further two 
genes, VLGR1 and TNEP1, also contain a variable number of the EPTP 
repeats (Staub et al., 2002). 
Remarkably, most of the mutations found in LGI1/Epitempin greatly 
alter the primary structure of the protein (Gu et al., 2002; Kalachikov et al., 
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2002; Morante-Redolat et al., 2002; Fertig et al., 2003; Kobayashi et al., 
2003; Michelucci et al., 2003; Berkovic et al., 2004; Hedera et al., 2004; 
Ottman et al., 2004). Eight out of 19 published mutations provoke a 
truncation of the protein either by altering the reading frame of the mRNA 
due to the existence of insertions or deletions (5 mutations) by introducing a 
nonsense mutation (1 mutation), or by a single-base mutation affecting a 
consensus splice site (2 mutations). The remaining eleven are missense 
mutations found in different domains of the protein. In addition to these 
kindreds with mutations in LGI1/Epitempin, other pedigrees with a 
phenotype that is consistent with ADLTE, show no mutations in this gene nor 
evidence for linkage to 10q24 (Morante-Redolat et al., 2002). Moreover, 
Bisulli and colleagues demonstrated that LGI1 does not modify the 
susceptibility for sporadic lateral temporal epilepsy (Bisulli et al., 2004). The 
clinical heterogeneity observed between these pedigrees could be explained 
by the existence of other genetic factors underlying the disease process. In 
this paper, we describe the analysis of the LGI/Epitempin family of genes in 
those pedigrees without mutations in LGI1/Epitempin, and in a population of 
sporadic patients affected by lateral temporal epilepsy. 
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2. Material & Methods. 
2.1. Familial cases and control populations for familial cases. 
As previously described, we collected pedigrees showing the Mendelian 
transmission of a phenotype that is consistent with ADLTE (Morante-Redolat 
et al., 2002; Poza et al. submitted). In brief, we collected families in which 
at least two individuals suffered from epilepsy, and if at least one of them 
suffered from partial auditory seizures in the absence of other neurological 
signs at clinical examination, and also with no known structural brain 
anomalies. By applying these criteria, 12 families have been identified to 
date (7 from Spain, 4 from Italy and 1 from Germany). No mutations in 
LGI1 were found in any of these families (Morante-Redolat et al., 2002). In 
order to determine the probability that any of the variants identified in the 
analysis of the familial sample was pathogenic, we also collected a sample of 
ethnically matched neurologically normal controls consisting of 30 individuals 
of Basque descent (9 male, mean age at collection: 50.29 ± 10.27 years), 
and of 30 individuals of Spanish descent (17 male, mean age at collection 
74.44 ± 10.92 years). 
2.2. Sporadic cases and control population for sporadic cases. 
The sporadic population was collected as described in (Bisulli et al., 
2004). Briefly, 38 patients (20 male, mean age at onset 19 (range 6-39)) 
and 41 healthy controls (19 male, mean age 24.9±5.9 (range 12-38)) all of 
Italian descent were identified, collected and analyzed as part of this study. 
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Mutation screening 
One case affected by each pedigree was analyzed for mutations in 
LGI1/Epitempin by the direct sequencing of coding exons, as previously 
described (Morante-Redolat et al., 2002). Those without mutations 
underwent a further analysis for mutations in the rest of the LGI gene family 
members (primer sequences and PCR conditions employed for the analysis 
are available upon request to JP-T). All primers were designed to be able to 
sequence each coding exon together with at least 50 bases of the flanking 
introns. Primers were designed with the aid of GeneRunner 
(http://wwww.generunner.com) using the following Ensembl sequences 
LGI2: ENSG00000153012; LGI3: ENSG00000168481; LGI4: 
ENSG00000153902. PCR products were purified with the QIAquick PCR 
purification kit (Qiagen), and were subjected to cycle sequencing with 
fluorescently labeled dideoxynucleotides (ABIPrism BigDye v3.0, Applied 
Biosystems) in both senses. Sequencing products were then purified by 
filtration on Montage-Seq96 plates (Millipore), subjected to electrophoresis 
on an ABIPrism 3100 Genetic Analyzer, and were finally processed with the 
software provided (Applied Biosystems). 
2.3. Analysis of polymorphisms 
The population analysis of the changes identified in the sequencing of 
LGI1/Epitempin paralogues was performed either by RFLP when possible, or 
by the amplification refractory mutation system (Newton et al., 1989) when 
a restriction digest was unsuitable. Table 1 shows the details of the assays 
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designed to genotype those polymorphisms in a series of healthy unrelated 
individuals. 
All polymorphic positions are numbered according to the reference 
sequences from the ENSEMBL web site (http://www.ensembl.org); LGI2: 
ENST00000282970, LGI3: ENST00000306317 and LGI4: ENST00000310123 
3. Results 
No pathogenic variant was found in any of the pedigrees. The 
sequencing of the LGI gene family in those families without mutations in 
LGI1/Epitempin allowed us to identify 8 variants (Figure 1), three of which 
were not in dbSNP. In an attempt to investigate whether the genetic 
variability found by sequencing the index case from each family was related 
to the disease in these families, we analyzed the segregation of each 
polymorphism with the disease in each of the pedigrees, and no co-
segregation of the disease was found with any of the polymorphisms (Table 
2). Further proof that none of the variants is related to the appearance of 
the epileptic phenotype in our families is seen with the presence of those 
same variants in a healthy population. As Table 3 shows, all the analyzed 
polymorphisms were also found in the general population regardless of their 
ethnic origin. 
We then tested whether the polymorphisms identified in the LGI gene 
family could be related to an increase in the risk of the disease by using a 
case-control approach. We studied a population of 38 Italian sporadic 
patients who were previously analyzed for the presence of mutations in 
LGI1/Epitempin (Bisulli et al., 2004), and we compared the genotypic and 
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allelic distributions with those obtained from a sample of 41 ethnically 
matched healthy controls. All genotypes were in Hardy-Weinberg equilibrium 
in both the case and control populations. Table 4 summarizes the result of 
this analysis. None of the polymorphisms showed a significant association 
with the disease in the LTE population. 
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4. Discussion. 
Autosomal dominant lateral temporal epilepsy (ADLTE) is caused by 
mutations in LGI1/Epitempin, a protein that belongs to the superfamily of 
the leucine-rich repeat containing proteins. LGI1/Epitempin mutations 
represent a new paradigm in epilepsy research, as this epilepsy-causing 
gene does not encode a molecule that is directly involved in 
neurotransmission such as an ion channel or a neurotransmitter receptor.  
Our data strongly suggest that the remaining members of the 
LGI1/Epitempin gene family do not confer an increased susceptibility with 
respect to ADLTE in those families without mutations in LGI1. These results 
are well in accordance with a similar study performed by Berkovic and 
colleagues (Berkovic et al., 2004) who neither found any pathogenic 
mutation in any LGI1 paralog in 2 ADLTE families nor an association 
between any of the polymorphisms found during the gene sequencing 
performed in a population of sporadic patients suffering from temporal lobe 
epilepsy. Interestingly enough, LGI4 has been associated with both the 
familial and sporadic forms of childhood absence epilepsy (CAE) (Gu et al., 
2004). The lack of genetic association between the different analyzed 
polymorphisms and LTE in our population could be the consequence of 
limited statistical power to detect such an association, or alternatively, that 
these genes are not involved in LTE. Regarding this point, as LGI1 has also 
been involved in the appearance of malignant glioblastoma, it is possible 
that the paralogues could also be involved in that particular phenotype or 
with other forms of epilepsy.  
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The lack of relationship between LGI2-4 and LTE could also be 
explained by the fact that these genes not only exhibit an overlapping, but  
also a distinct expression pattern in certain cases (Senechal et al., 2005). 
This suggests that the different members of this gene family might be 
related to other neurological phenotypes characterized by alterations in the 
same anatomical area where they are expressed. Moreover, our results do 
not imply that these genes might not be related to other disorders. In fact, 
Gu et al. have recently shown that this gene family is strongly conserved 
through evolution, which underlines the importance of its biological function, 
and also suggests that they may be involved in certain disorders (Gu et al., 
2005). 
In conclusion, our analysis shows that with the exception of LGI1 in ADLTE, 
the LGI gene family is not involved in the appearance of either familial or 
sporadic LTE. Further work in a larger population is needed in order to 
definitely rule out any genetic effect that this gene family may have on the 
development of this disorder. Nevertheless, the two additional genes with 
EPTP repeats remain as valid candidates for this disease. This could be 
especially true for the VLGR1 protein as it has been shown that a mutation 
in one of the EPTP repeats in this protein is the cause of a natural model of 
audiogenic epilepsy (Skradski et al., 2001). 
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Figure 1. Genomic organization of the LGI2, LGI3 and LGI4 genes. 
The positions of the polymorphisms identified in this work are shown. Gray 
boxes represent coding exons (drawn to scale), whereas a thin line 
represents introns (not drawn to scale). 
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Table 1. Assays designed to study the LGI gene family polymorphisms. 
 
Gene Localization Change dbSNPa Assayb Sense primerc Antisense primerc Conditions 
LGI2 Intron 3 c.341+18T>C rs ARMS TGTTTGCCCACAGATCAAAA CCGAATGTTCAGCGAATAG(A/G) 60x30c 
        
LGI3 Intron 4 c.422+60 A>C rs BsrD I  ACACGGGCTGAAATCTAG CCATCCCAATTCTGACTC 55x35c 
        
LGI4 Intron 2 c.242+47 A>G rs11666576 ARMS CCCACACATGTGCATAA(C/T) AATGCCCACCTGACATCT F1:60x30ce 
F2:56x35ce 
 Exon 5 c.456 T>C 
(p.H151H) 
rs1673007 Eco72 I CAGTGGGCCTATGTCTTT AAGAAAAATACGTAAGAACCA 50x35c 
 Exon 8 c.834 G>C 
(p.277P) 
rs1687998 EcoO109 I TTCTGCCTGTCCAGCAG AGGTCAGAGTTTAGAGGCTT 55x35c 
 Exon 8 c.960 C>G 
(p.A319A) 
rs BstU I  TTCTGCCTGTCCAGCAG AGGTCAGAGTTTAGAGGCTT 55x35c 
 Exon 8 c.1203 A>G 
(p.T400T) 
rs1319969 ARMS GCTTCGAGAGACGCAC(G/A) TAGGTCAGAGTTTAGAGGCTT 60x30c 
 Exon 9f c.1395 GC>AT 
(p.Q,L464,465Q,L) 
rs12610146 
rs12610234 
Alu I  CTTCTGCTTCCAAGCTGT CATCACCCCAAGTAGGG 55x35c 
a: SNPs identified as part of this  study. In italic, new SNPs identified in this study and submitted to dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
b: Assay refers to the method employed for the genotyping of each polymorphism. ARMS: allele-specific PCR, rest, restriction digest performed with the indicated restriction 
enzyme according to the manufacture’s instructions. 
c: The alle le-specific base is indicated in brackets. For each SNP two different reactions were performed with a common primer combined with each of the alternative primers.  
d:  It was necessary to use diffe rent PCR conditions for each allele-specific reaction to obtain a specific result. R1:A-a lle le, R2: G-allele 
e:  It was necessary to use different PCR conditions for each allele-specific reaction to obtain a specific result. F1:C-alle le, F2: T-allele 
f: Variants rs12610146 and rs12610234 always appear together in the same individual, possibly in the same allele. 
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Table 2. Appearance and segregation with disease of polymorphisms in the LGI/Epitempin gene family in 
the familial sample. 
 
LGI2* LGI3* LGI4* 
Family Origin C.341+18 
T>C 
c.422+60 
A>C 
c.242+47 
A>G 
c.456 
T>C 
c.834 
G>C 
c.960 
C>G 
c.1203 
A>G 
c.1395 
GC>AT 
ESP1 Basque   ✧  ✧  ✧ ✧ 
ESP2 Basque         
ESP3 Basque ✧        
ESP4 Basque ✧    ✧  ✧  
ESP5 Basque ✧  ✧      
ESP6 Basque ✧ ✧ ✧  ✧  ✧ ✧ 
ESP7 Basque ✧ ✧  ✧ ✧ ✧ ✧ ✧ 
ITA1 Italian        ✧ 
ITA2 Italian         
ITA3 Italian        ✧ 
ITA4 Italian ✧ ✧       
DEU1 German 
  ✧     ✧ 
 
* : not present in the family; ✧: present in that family. 
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Table 3. Allelic and genotypic distribution of polymorphisms found in the LGI/Epitempin 
family members in the familial control populations. 
 
Genotype frequencies* 
(N (%)) 
Allele frequencies* 
(%) Polymorphism 
Control 
Population 
W/W W/M M/M W M 
LGI2       
c.341+18 T>C Basque  22 (73.3) 6 (20.0) 2 (6.6) 83.3 16.6 
 Non-Basque 22 (73.3) 8 (26.7) 0 (0.0) 86.6 13.3 
       
LGI3       
c.422+60A>C Basque  20 (66.6) 9 (30.0) 1 (3.3) 81.6 18.3 
 Non-Basque 18 (60.0) 10 (33.3) 2 (6.6) 76.8 23.2 
       
LGI4       
c.242+47A>G Basque  10 (33.3) 11 (36.6) 9 (30.0) 51.6 48.3 
 Non-Basque 11 (36.6) 13 (43.3) 6 (20.0) 58.3 41.6 
c.456T>C Basque  27 (90.0) 3 (10.0) 0 (0.0) 95.0 5.0 
 Non-Basque 25 (83.3) 5 (16.6) 0 (0.0) 91.6 8.3 
c.834G>C Basque  16 (53.3) 12 (40.0) 2 (6.6) 73.3 26.6 
 Non-Basque 13 (43.3) 17 (56.6) 0 (0.0) 71.6 28.3 
c.960C>G Basque  28 (93.3) 2 (6.6) 0 (0.0) 96.6 3.3 
 Non-Basque 29 (96.6) 1 (3.3) 0 (0.0) 98.3 1.7 
c.1203A>G Basque  16 (53.3) 12 (40.0) 2 (6.6) 73.3 26.6 
 Non-Basque 13 (43.3) 17 (56.6) 0 (0.0) 71.6 28.3 
c.1395GC>AT Basque  17 (56.8) 11 (36.6) 2 (6.6) 75.1 24.9 
 Non-Basque 19 (63.4) 9 (30.0) 2 (6.6) 78.4 21.6 
*: W refers to the wild-type allele of each polymorphism. M refers to the mutant allele at that same 
polymorphism. 
A. Ayerdi-Izquierdo, 20 
 
Table 4. Allelic and genotypic distribution of polymorphisms found in the LGI/Epitempin family members in the 
sporadic Italian LTE cases and controls. 
 
Genotype frequenciesa,* 
(N (%)) 
Allele frequencies*  
(%) Polymorphism 
Control 
Population 
W/W W/M M/M P W M P 
LGI2         
c.341+18 T>C LTE cases 28 (73.3) 8 (20.0) 3 (6.6) 0.733 84.5 15.5 0.724 
 Controls 28 (68.8) 13 (31.7) 0 (0.0)  84.6 15.3  
         
LGI3         
c.422+60A>C LTE cases 26 (67.6) 10 (27.0) 2 (5.4) 0.489 81.1 18.9 0.861 
 Controls 25 (61.0) 16 (39.0) 0 (0.0)  80.5 19.5  
         
LGI4         
c.242+47A>G LTE cases 14 (36.6) 14 (36.6) 10 (26.8) 0.725 54.9 45.1 0.678 
 Controls 15 (36.6) 18 (43.9) 8 (19.5)  58.5 41.5  
c.456T>C LTE cases 30 (80.0) 6 (16.6) 1 (3.3) 0.993 88.3 11.6 0,864 
 Controls 33 (80.5) 7 (17.1) 1 (2.4)  89.0 11.0  
c.834G>C LTE cases 22 (56.6) 16 (43.2) 1 (2.7) 0.978 76.6 23.3 0.795 
 Controls 23 (56.1) 18 (43.9) 0 (0.0)  78.0 22.0  
c.960C>G LTE cases 37 (97.3) 1 (2.7) 0 (0.0) 0.663 98.6 1.3 0.349 
 Controls 38 (92.7) 3 (7.3) 0 (0.0)  96.3 3.7  
c.1203A>G LTE cases 22 (56.6) 15 (40.0) 1 (3.3) 0.705 76.6 23.3 0.934 
 Controls 22 (53.7) 19 (46.3) 0 (0.0)  76.8 23.2  
c.1395GC>AT LTE cases 22 (56.6) 13 (33.3) 4 (10.0) 0.287 73.3 26.7 0.166 
 Controls 16 (39.0) 20 (48.8) 5 (12.2)  63.4 36.6  
a: For those values in italics, the chi-square test has 1df either because of the low number or the complete absence of the 
individuals’  homozygous genotype for the rare allele. The analysis was performed by grouping heterozygous and homozygous 
genotypes for the rare allele. 
*: W refers to the wild-type allele of each polymorphism. M refers to the mutant allele at that same polymorphism. 
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